alexa [Usefulness of metformin in diabetes-related bone disease].
Pharmaceutical Sciences

Pharmaceutical Sciences

Pharmaceutica Analytica Acta

Author(s): Kanazawa I

Abstract Share this page

Abstract Accumulative evidence shows that type 2 diabetes patients have high fracture rate in spite of the absence of bone mineral density (BMD) reduction. The etiology and treatment of diabetes-related bone disease have recently attracted widespread attention. Recent epidemiologic studies have shown that the fracture rate was decreased in patients treated with metformin, one of the anti-hyperglycemic agents by improving insulin resistance. Several studies have indicated that metformin directly stimulated the differentiation of osteoblastic cells, and that metformin reversed deleterious effects of advanced glycation end products on these cells. Further longitudinal studies are needed to clarify the effects of metformin on BMD, bone turnover markers, and fracture risks in type 2 diabetes. This article was published in Clin Calcium and referenced in Pharmaceutica Analytica Acta

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version